This technology is a humanized monoclonal antibody and an improved fusion protein-based vaccine for the prevention and treatment of measles.
Despite the availability of effective vaccines, measles remains a significant global health concern, particularly in populations with inadequate vaccination coverage. Severely immunocompromised individuals are especially vulnerable because live-attenuated measles vaccines are generally contraindicated in this population. In addition, measles can cause severe complications, including central nervous (CNS) disease, and there is currently no approved specific antiviral therapy for measles. There is therefore a need for targeted antiviral treatments and alternative approaches to protect individuals who cannot safely receive existing measles vaccines.
This technology is a humanized monoclonal antibody against the measles viral entry receptor which prevents viral spread. This technology can be administered either prophylactically or post-exposure to measles to reduce infection and improve health outcomes. Furthermore, this technology includes an improved measles virus fusion protein that demonstrates a functional relationship between viral fusion, its stability, and activity. This technology forms the basis of novel vaccination strategies or inhibitory molecule development.
This technology has been tested in cotton rats.
Patent pending
IR CU23244, CU23245, CU24384, CU26279
Licensing Contact: Kristin Neuman
